【摘要】 目的：评估石杉碱甲片治疗阿耳茨海默病的疗效及其安全性.方法:采用多中心、前瞻性、双盲、平行、空白对照和随机方法,给50例阿尔采末病一日两次口服石杉碱甲片4片(每片含50微克),并给53例阿耳茨海默病一日两次口服安慰剂片4片,共8wk.所有病人都用韦氏智力量表、简易精神状态量表、长谷川痴呆量表、日常生活能力量表、副反应量表和其他实验室检查.结果:发现58％(29/50)的石杉碱甲片服用者改善了所有的记忆、认知和行为能力,而安慰剂组仅为35.8％(19/53),两组疗效有显著差异(X~2=5.07,P<0.05),而两组均无严重不良反应发生.结论:石杉碱甲片显著增高记忆、认知和行为功能,是治疗阿耳茨海默病的一个有前景的药物.更多还原

【Abstract】 AIM:To evaluate the efficacy and safety of tablet huperzine-A (Hup) in patients with Alzheimer’s disease. METHODS: Using mul-ticenter, prospective, double-blind, parallel, placebo controlled and randomized method, 50 patients were administrated orally 0. 2 mg (4 tablets) Hup and 53 patients were given po 4 tablets of placebo bid for 8 wk. All patients were evaluated with Wechsler memory scale, Hasegawa dementia scale, mini-mental state examination scale, activity of daily living scale, treatment emergency symptom scale, and measured with BP, HR, ECG, EEG, ALT, AKP, BUN, Cr, Hb, WBC, and urine routine. RESULTS: About 58 % (29/50) of patients treated with Hup showed improvements in their memory (P <0. 01), cognitive (P<0. 01), and behavioral (P<0. 01 functions. The efficacy of Hup was better than placebo (36 %, 19/53)(P<0. 05). No severe side effect was found. CONCLUSION: Hup is a promising drug for symptomatic treatment of Alzheimer’s disease.更多还原